MAPT and Alzheimer disease: In an animal model of AD (APP/PS1 mice), functional inhibition of TLR2 decreases microgliosis, astrogliosis, Aβ plaque deposition, and phosphorylated tau accumulation in the brain regions, thereby improving cognitive function19,87,88.